Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen (formaldehyde Inactivated)

For most adults, the standard dosage of a vaccine containing the Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen is a single 0.5 mL dose administered intramuscularly. This is typically given once per year, ideally before the onset of the peak influenza season (usually by the end of October in the Northern Hemisphere). For adults aged 65 and older, a 'high-dose' version may be administered, which contains a higher concentration of the antigen (typically 60 mcg of HA per strain instead of the standard 15 mcg) to compensate for the natural weakening of the immune system that occurs with age.

Pediatric dosing is strictly age-dependent and follows guidelines established by the CDC and FDA:

• Children 6 months through 8 years: If it is the child's first time receiving a flu vaccine, or if they have not previously received at least two doses of trivalent or quadrivalent influenza vaccine before July 1 of the current year, they require two doses. These doses must be administered at least 4 weeks apart. The second dose is necessary to 'prime' the immune system for a robust response. The volume per dose is typically 0.5 mL, though some older formulations used 0.25 mL for very young children.
• Children 9 years and older: A single 0.5 mL dose is sufficient, regardless of previous vaccination history.
• Infants under 6 months: This antigen is NOT approved for use in infants under 6 months of age, as their immune systems do not respond effectively to the vaccine and safety has not been established in this cohort.

Renal Impairment

No dosage adjustments are required for patients with renal impairment. The antigen is not cleared by the kidneys, and clinical studies have shown that the vaccine is safe for patients with various stages of chronic kidney disease, including those on dialysis.

Hepatic Impairment

No dosage adjustments are necessary for patients with hepatic impairment. Liver function does not affect the processing of the inactivated viral antigen or the subsequent immune response.

Elderly Patients

While the dose volume remains 0.5 mL, healthcare providers often recommend the 'High-Dose' or 'Adjuvanted' versions of the vaccine for patients over 65. These are specifically formulated to improve the antibody titer levels in the geriatric population.

This medication is administered exclusively by a healthcare professional. It is given as an intramuscular (IM) injection. The preferred site for adults and older children is the deltoid muscle (upper arm). For infants and younger children, the anterolateral aspect of the thigh is preferred due to greater muscle mass.

• Preparation: The vial or syringe should be shaken well before administration to ensure the suspension is uniform. It should appear as a milky, white liquid.
• Storage: The vaccine must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). It must NEVER be frozen. If the vaccine has been frozen, it must be discarded as the antigen structure may be compromised.
• Administration: The site should be cleaned with alcohol. The needle is inserted at a 90-degree angle to ensure it reaches the muscle tissue.

Since this is an annual vaccine, there is no 'missed dose' in the traditional sense. However, if you miss the early window for vaccination, you should receive the dose as soon as possible during the flu season. Even late-season vaccination (January or February) can provide protection as flu activity often peaks late.

An overdose of an inactivated viral antigen is highly unlikely as it is administered by healthcare professionals in pre-measured doses. In the event of an accidental double dose, the primary risk is an increase in the severity of local injection site reactions (swelling, pain) or systemic symptoms (fever). There is no specific 'antidote'; management is supportive (e.g., acetaminophen for fever).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Side effects from Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen are generally mild and are a sign that the body is building protection. The most common reaction is injection site pain, which occurs in over 60% of recipients. This typically feels like a dull ache in the deltoid muscle and usually resolves within 24 to 48 hours. Other common effects include:

• Erythema (Redness): A small red patch at the site of injection.
• Induration (Hardness): A firm feeling at the injection site.
• Fatigue: A general feeling of tiredness or lethargy as the immune system activates.
• Headache: Usually mild and responsive to over-the-counter pain relievers.
• Myalgia (Muscle Aches): Generalized body aches, distinct from the injection site.

• Low-grade Fever: Typically defined as a temperature between 100°F and 101°F. This is more common in children receiving their first dose.
• Nausea: Mild stomach upset or loss of appetite shortly after vaccination.
• Shivering/Chills: Often accompanying the onset of a mild fever.
• Arthralgia: Joint pain, which is usually transient.

• Lymphadenopathy: Swelling of the lymph nodes, usually in the armpit (axilla) on the side where the shot was given.
• Urticaria: Hives or an itchy rash that may appear shortly after administration.
• Syncope: Fainting, particularly in adolescents, often triggered by the process of injection rather than the antigen itself.

While extremely rare, serious reactions can occur. You must seek emergency care if you experience:

• Anaphylaxis: Symptoms include difficulty breathing, swelling of the face or throat, rapid heartbeat, and a severe rash. This usually occurs within minutes of the injection.
• Guillain-Barré Syndrome (GBS): A rare neurological disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis. Symptoms often start as tingling or weakness in the legs.
• Brachial Plexus Neuropathy: Severe pain in the shoulder and upper arm followed by weakness or numbness.
• High Fever: A temperature exceeding 103°F.

> Warning: Stop taking Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen (formaldehyde Inactivated) and call your doctor immediately if you experience any of these.

There are no known long-term side effects associated with the A/Thailand/8/2022 antigen. Because the antigen is cleared from the body within days and the immune response (antibodies) is a natural biological product, there is no evidence of chronic health issues resulting from annual influenza vaccination. Studies monitoring millions of doses have confirmed the long-term safety profile of inactivated influenza antigens.

No FDA black box warnings for Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen (formaldehyde Inactivated). This product is considered safe for the general population when administered according to guidelines.

Report any unusual symptoms to your healthcare provider. In the United States, side effects can also be reported to the Vaccine Adverse Event Reporting System (VAERS).

Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen is intended for the prevention, not the treatment, of influenza. It will not treat an active flu infection. Patients should be screened for any acute febrile illness (fever) before administration; while a minor cold is not a contraindication, moderate to severe illness may warrant delaying the vaccination until the patient has recovered.

No FDA black box warnings for Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen (formaldehyde Inactivated).

• Allergic Reactions / Anaphylaxis Risk: Although rare, severe allergic reactions can occur. If the antigen was produced using an egg-based process, individuals with a history of severe egg allergy (anaphylaxis) should be vaccinated in a medical setting supervised by a healthcare provider who can recognize and manage severe allergic reactions. However, most people with egg allergies can safely receive the vaccine.
• Guillain-Barré Syndrome (GBS): If GBS has occurred within 6 weeks of a previous influenza vaccination, the decision to give the A/Thailand/8/2022 antigen should be based on careful consideration of the potential benefits and risks.
• Immunocompromised Patients: Individuals with weakened immune systems (due to HIV, cancer, or immunosuppressive drugs) may have a reduced immune response to the vaccine. While the vaccine is safe for these patients (as it is inactivated), it may not be as effective in preventing the flu.
• Syncope (Fainting): Fainting can occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting, such as keeping the patient seated for 15 minutes post-injection.

There are no routine lab tests (like blood counts or liver enzymes) required after receiving this antigen. Monitoring is primarily clinical:

• Immediate Post-Injection Observation: Patients are typically observed for 15-20 minutes to monitor for signs of an immediate allergic reaction or fainting.
• Temperature Monitoring: Parents of young children should monitor for fever in the 24 hours following vaccination.

This antigen has no known effect on the ability to drive or operate machinery. However, if a patient experiences syncope (fainting) or significant fatigue after the injection, they should avoid these activities until symptoms resolve.

There is no direct interaction between alcohol and the A/Thailand/8/2022 antigen. However, excessive alcohol consumption can suppress the immune system, potentially reducing the body's ability to mount an effective response to the vaccine. It is generally advised to avoid heavy drinking immediately before or after vaccination.

As this is a single-dose (or two-dose for children) vaccine, 'discontinuation' is not applicable in the way it is for daily medications. However, if a patient has a severe reaction to the first dose of a two-dose pediatric series, the second dose should be withheld.

> Important: Discuss all your medical conditions with your healthcare provider before starting Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen (formaldehyde Inactivated).

There are no absolute drug-drug contraindications that would result in a life-threatening interaction. However, the vaccine should not be administered simultaneously with other vaccines in the same syringe. Each vaccine must be given at a separate anatomical site.

• Immunosuppressant Medications: Drugs such as high-dose corticosteroids (e.g., prednisone >20mg/day), chemotherapy agents, and biologics used for autoimmune diseases (e.g., TNF inhibitors) can significantly blunt the immune response to the A/Thailand/8/2022 antigen. The clinical consequence is reduced vaccine efficacy. Healthcare providers may recommend timing the vaccine during a 'window' when immunosuppression is at its lowest.
• Anticoagulants (Blood Thinners): Medications like warfarin, apixaban, or heparin do not interact with the antigen itself but increase the risk of hematoma (a large bruise or collection of blood) at the injection site. A fine-gauge needle should be used, and firm pressure applied for at least two minutes post-injection.

• Other Inactivated Vaccines: While most vaccines can be given at the same time, co-administration with certain vaccines (like the pneumococcal vaccine) may slightly increase the risk of systemic reactions like fever.
• Statins: Some studies suggest that patients on chronic statin therapy may have slightly lower antibody titers following influenza vaccination, though this is not currently a reason to alter statin use or vaccination schedules.

There are no known interactions with food, including grapefruit, dairy, or caffeine. The processing of the antigen is entirely independent of the digestive system.

• Echinacea and Elderberry: While often taken to 'boost' the immune system, there is no clinical data suggesting they interfere with the A/Thailand/8/2022 antigen. However, patients should inform their doctor if they are taking high doses of any immune-modulating supplements.
• St. John's Wort: No known interaction with inactivated viral antigens.

• Influenza Diagnostic Tests: Because the antigen is inactivated and administered intramuscularly, it will NOT cause a false-positive result on a rapid influenza diagnostic test (RIDT) or PCR test. If a patient tests positive for flu shortly after vaccination, it is likely due to a pre-existing infection or exposure to a different strain.
• HIV/HCV/HTLV-1 Screening: Rare instances of transient false-positive results on ELISA screening tests for HIV-1, Hepatitis C, and HTLV-1 have been reported following flu vaccination. These are due to cross-reactive IgM antibodies and are clarified by more specific confirmatory tests (like Western Blot or PCR).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen must NEVER be used in the following circumstances:

• Severe Allergic Reaction (Anaphylaxis): Any individual who has had a documented anaphylactic reaction to a previous dose of an influenza vaccine or to any component of the vaccine (including formaldehyde, which is used in the inactivation process, or antibiotics like neomycin used in manufacturing) must not receive this antigen.
• Infants under 6 months: The safety and efficacy have not been established, and the immune system of a young infant is generally unable to mount a protective response to this inactivated antigen.

These conditions require a careful risk-benefit analysis by a physician:

• Guillain-Barré Syndrome (GBS): A history of GBS within 6 weeks of a previous flu shot is a precaution. If the patient is at high risk for severe flu complications, the doctor may still recommend vaccination.
• Moderate to Severe Acute Illness: Vaccination should be deferred until the acute symptoms have resolved to avoid diagnostic confusion between the illness symptoms and potential vaccine side effects.

• Formaldehyde Sensitivity: Since formaldehyde is used to inactivate the virus, trace amounts may remain. Individuals with known contact dermatitis or systemic sensitivity to formaldehyde should consult an allergist.
• Egg Protein: For egg-based versions of the antigen, trace amounts of ovalbumin may be present. While most egg-allergic individuals can receive the vaccine, those with severe reactions should use egg-free (cell-based or recombinant) alternatives if available.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen (formaldehyde Inactivated).

Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen is strongly recommended for pregnant individuals. Pregnancy increases the risk of severe complications from the flu due to changes in the immune system, heart, and lungs.

• Safety: Extensive data from decades of use of inactivated flu vaccines show no increased risk of miscarriage, birth defects, or pregnancy complications.
• Benefit: Vaccination during pregnancy provides 'passive immunity' to the newborn. The mother’s antibodies cross the placenta and protect the infant during their first six months of life when they are too young to be vaccinated themselves.

Inactivated influenza antigens do not pass into breast milk in a way that would affect the infant. Breastfeeding is not a contraindication. In fact, vaccinated mothers may pass some protective antibodies through breast milk, providing an extra layer of defense for the nursing child.

This antigen is approved for children 6 months and older. It is a critical tool in reducing pediatric flu hospitalizations. For children under 9 receiving the vaccine for the first time, a two-dose schedule is mandatory for efficacy. Growth and developmental effects have been studied, and no adverse impacts have been found.

Patients aged 65 and older are at the highest risk for flu-related death. While the A/Thailand/8/2022 antigen is safe for this group, the standard dose may be less effective due to immunosenescence (age-related immune decline). Consequently, high-dose or adjuvanted formulations are preferred for this population to ensure adequate antibody production.

Patients with renal impairment, including those on hemodialysis, are encouraged to receive the vaccine. No dose adjustment is needed, though the immune response may be slightly lower than in healthy controls.

No adjustments are needed for patients with liver disease. The antigen is processed locally and via the lymphatic system, bypassing hepatic metabolic pathways.

> Important: Special populations require individualized medical assessment.

The Influenza A Virus A/thailand/8/2022 Ivr-237 (h3n2) Antigen acts as an immunogen. The formaldehyde inactivation process ensures the viral RNA is unable to replicate, but the surface proteins—specifically Hemagglutinin (HA)—remain antigenically intact. The HA protein normally facilitates viral entry by binding to sialic acid receptors on human respiratory cells. By introducing these HA proteins to the immune system, the vaccine induces the production of IgG antibodies. These antibodies provide 'sterilizing immunity' by binding to the HA protein of any invading H3N2 virus, effectively blocking the virus's ability to attach to host cells.

• Onset of Effect: Protective antibody titers (typically defined as a hemagglutination inhibition [HI] titer of 1:40 or greater) are usually achieved within 10 to 14 days post-vaccination.
• Duration of Effect: Immunity typically lasts for 6 to 12 months. This decline, combined with the 'antigenic drift' (mutation) of the virus, necessitates annual revaccination.
• Tolerance: There is no pharmacological tolerance; however, repeated annual exposures can lead to a 'broadening' of the immune response to related H3N2 strains.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intramuscular Injection) |

| Protein Binding | N/A (Biological Antigen) |

| Half-life | Days (Antigenic fragments) |

| Tmax | 14 days (Peak Antibody Titer) |

| Metabolism | Proteolysis in APCs |

| Excretion | Reticuloendothelial clearance |

The antigen consists of purified viral fragments. The molecular weight of the HA trimer is approximately 220 kDa. It is soluble in phosphate-buffered saline (PBS) and may contain trace amounts of formaldehyde (less than 100 mcg) and sucrose.

This antigen is classified as a Viral Vaccine Component. It is part of the broader EPC class: Non-Standardized Plant Allergenic Extract [EPC] (as categorized in some regulatory databases), though it is clinically managed as an Inactivated Viral Biological.